CAS Number82410-32-0
SynonymsVitrasert; Gancyclovir; HHEMG; T56 BN DN FN HNJ D1OY1Q1Q GZ IQ; MFCD00870588; Ganciclovir; Cymevene; bwb759u; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-3,9-dihydro-6H-purin-6-one; 2'-ndg; DHPG; biolf62; T56 BN DN FVM INJ B1OY1Q1Q HZ; cymevan; Cytovene; 2-Amino-9-{[(1,3-dihydroxy-2-propanyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; BW B759U; bw-759u; GVC; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one; 2-[(6-Hydroxy-2-imino-2,3-dihydro-9H-purin-9-yl)methoxy]-1,3-propanediol; bw-759
Molecular FormulaC9H13N5O4
Molecular Weight255.23
Purity≥99 (HPLC)%
Density1.8±0.1 g/cm3
Boiling Point657.0±65.0 °C at 760 mmHg
Melting Point250°C
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 82410-32-0 |
| Catalog No. | 2A-9010685 |
| Chinese Name | 更昔洛韦 |
| Synonyms | Vitrasert; Gancyclovir; HHEMG; T56 BN DN FN HNJ D1OY1Q1Q GZ IQ; MFCD00870588; Ganciclovir; Cymevene; bwb759u; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-3,9-dihydro-6H-purin-6-one; 2'-ndg; DHPG; biolf62; T56 BN DN FVM INJ B1OY1Q1Q HZ; cymevan; Cytovene; 2-Amino-9-{[(1,3-dihydroxy-2-propanyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; BW B759U; bw-759u; GVC; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; 2-Amino-1,9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one; 2-[(6-Hydroxy-2-imino-2,3-dihydro-9H-purin-9-yl)methoxy]-1,3-propanediol; bw-759 |
| Molecular Formula | C9H13N5O4 |
| Molecular Weight | 255.23 |
| Purity | ≥99 (HPLC) |
| Density | 1.8±0.1 g/cm3 |
| Boiling Point | 657.0±65.0 °C at 760 mmHg |
| Melting Point | 250°C |
| Appearance | powder |
| Water Solubility | 0.1 M HCl: 10 mg/mL |
| Storage Condition | Refrigerated, airtight, dry place at 2-8°C |
| Application | Ganciclovir is a potent inhibitor of herpes simplex viruses (HSV), including cytomegalovirus (CMV), with an IC50 value of 5.2 μM against FHV-1. |
| HTC | 2933990090 |
| UN(IATA) | NA |
| PubChem ID | 24278453 |
| MDL Number | MFCD00870588 |
| SMILES | NC1=Nc2c(ncn2COC(CO)CO)C(=O)N1 |
| InChI | 1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17) |
| InChI Key | IRSCQMHQWWYFCW-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | Transport |
| MSDS | msds/10685_1_82410_32_0.pdf |
| Bioactivity | Ganciclovir is a potent herpes simplex virus (HSV)inhibitor, including cytomegalovirus (CMV), with an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1). Related Catalog Signaling Pathways >> Anti-infection >> HSV Research Areas >> Infection Target IC50: 5.2 μM (FHV-1)[1] In Vitro Ganciclovir is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 mumol versus 72 mumol for acyclovir[2].The primary mechanism of ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase.Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase[3]. In Vivo In adult rats, the intracochlear diffusion of ganciclovir is shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion is observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of ganciclovir shows a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but becomes undetectable by 2 h after injection. Counts of white blood cells, red blood cells and platelets decreases significantly in ganciclovir-treated newborn mice[4]. Animal Admin Rats: Two albino rats non-immunized for MCMV are used in the study. After being weighed, two adult rats undergo peritoneal injections. The first rat receives 50 mg/kg of ganciclovir twice a day (i.e. 100 mg/kg/day), for a total of 3 days or 6 injections. The second rat is used as a negative control and received intraperitoneal injections of glucose solution. After the 6th injection, the two rats are sacrified; blood and perilymphatic fluids are collected for analysis[4]. Mice: Non-inbred Oncins France 1 (OF1) mice are used in the study. Ganciclovir is diluted in 5% glucose serum to a concentration of 5 mg/mL and administered intraperitoneally in newborn mice at a dose of 50 mg/kg twice a day. Five injections are administered in total[4]. References [1]. Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [2]. Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12. [3]. Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4. [4]. BoujemLa I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016 Aug;132:111-5. Chemical & Physical Properties Density 1.8±0.1 g/cm3 Boiling Point 657.0±65.0 °C at 760 mmHg Melting Point 250°C Molecular Formula C9H13N5O4 Molecular Weight 255.231 Flash Point 351.1±34.3 °C Exact Mass 255.096756 PSA 139.28000 LogP -3.62 Vapour Pressure 0.0±2.1 mmHg at 25°C Index of Refraction 1.761 Storage condition 2-8°C Water Solubility 0.1 M HCl: 10 mg/mL |
| Use of | Ganciclovir is a potent herpes simplex virus (HSV)inhibitor, including cytomegalovirus (CMV), with an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1). Properties Articles81 Name ganciclovir Synonym More Synonyms Ganciclovir Biological Activity Description Ganciclovir is a potent herpes simplex virus (HSV)inhibitor, including cytomegalovirus (CMV), with an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1). Related Catalog Signaling Pathways >> Anti-infection >> HSV Research Areas >> Infection IC50: 5.2 μM (FHV-1)[1] In Vivo In adult rats, the intracochlear diffusion of ganciclovir is shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion is observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of ganciclovir shows a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but becomes undetectable by 2 h after injection. Counts of white blood cells, red blood cells and platelets decreases significantly in ganciclovir-treated newborn mice[4]. References [1]. Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [2]. Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12. [3]. Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4. [4]. BoujemLa I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016 Aug;132:111-5. Chemical & Physical Properties Molecular Formula C9H13N5O4 Exact Mass 255.096756 PSA 139.28000 LogP -3.62 Index of Refraction 1.761 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Fulvestrant | 129453-61-8 | 2A-9010646 |
| Nystatin | 1400-61-9 | 2A-9010650 |
| Furosemide | 54-31-9 | 2A-9010663 |
| Gabapentin hydrochloride | 60142-96-3 | 2A-0200168 |
| gamma-Lumicolchicine | 6901-14-0 | 2A-9010682 |
| Ganciclovir sodium | 107910-75-8 | 2A-9010686 |
| Gatifloxacin lactate | 160738-57-8 | 2A-9010698 |
| Gefitinib | 184475-35-2 | 2A-9010701 |
| Gemcitabine | 95058-81-4 | 2A-9010704 |
| Gemcitabine hydrochloride | 122111-03-9 | 2A-9010705 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS